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4Abstract 
Most patients with HER2-positive breast or gastric cancer exhibit primary or acquired resistance to 
trastuzumab emtansine (T-DM1), and such patients may have limited therapeutic options. XMT-
1522 is a novel anti-HER2 antibody-drug conjugate. We compared XMT-1522 to T-DM1 in 
preclinical models. The effects of XMT-1522 and T-DM1 on cell survival and apoptosis were 
compared in six HER2-positive breast cancer or gastric cancer cell lines, of which three lines were 
T-DM1-sensitive (N-87, OE-19, JIMT-1) and three T-DM1-resistant (RN-87, ROE-19, SNU-216). 
We compared these agents also in the HER2-negative breast cancer cell line MCF-7, and in mouse 
RN-87 and JIMT-1 xenograft models. Cell survival was assessed using the AlamarBlue method and 
apoptosis with the Caspase-Glo 3/7 method. XMT-1522 inhibited the growth of all six HER2-
positive cell lines. The proportions of cells that survived XMT-1522 treatment were smaller as 
compared to T-DM1, particularly in the T-DM1-resistant cell lines. XMT-1522 induced more cell 
apoptosis compared to T-DM1. While RN-87 and JIMT-1 xenograft tumors progressed on T-DM1 
treatment, all tumors responded to XMT-1522, and all but one tumor disappeared during the XMT-
1522 treatment. XMT-1522 had a strong anti-tumor effect on RN-87 and JIMT-1 xenografts that 
progressed on T-DM1. We conclude that XMT-1522 was effective in HER2-positive breast cancer 
and gastric cancer cell lines resistant to T-DM1, and in xenograft models resistant to T-DM1. The 
results support the testing of XMT-1522 in clinical trials in patients with HER2-positive cancer. 
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5Introduction 
Overexpression and amplification of the human epidermal growth factor receptor-2 (HER2) is 
present in about 15-20% of human breast cancers and gastric cancers (1-3). Trastuzumab, a 
humanized monoclonal antibody that binds to the extracellular domain IV of HER2, has substantial 
anti-tumor activity, and is approved for the treatment of HER2-positive breast cancer and for 
HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma (4,5). Although 
responses to trastuzumab are often durable, most advanced cancers eventually become resistant to 
trastuzumab (6-8). 
Antibody-drug conjugates (ADC) can deliver cytotoxic payloads to cancer cells. Trastuzumab 
emtansine (T-DM1, Kadcyla) is an anti-HER2 ADC where trastuzumab is linked with DM1 (a 
derivative of maytansine) via a non-reducible thioether linker (9). One T-DM1 carries an average of 
3.5 DM1 moieties. DM1 and other T-DM1 catabolites such as MCC-DM1 (4-[N-
maleimidomethyl]cyclohexane-1-carbonyl-DM1) and lysine-MCC-DM1 are released following 
receptor-mediated internalization and lysosomal degradation of the conjugate (10). Intracellular 
DM1 is a potent inhibitor of the microtubule assembly thereby causing cell death (9,11). The U.S. 
Food and Drug Administration (FDA) approved T-DM1 as monotherapy for the treatment of 
patients with HER2-positive advanced breast cancer who had previously received trastuzumab and 
a taxane in 2013 (12,13). As with trastuzumab, the majority of the initially responding advanced 
breast cancers eventually became resistant to T-DM1 (12,13). Adjuvant T-DM1 was superior to 
trastuzumab in a randomized trial in patients with HER2-positive breast cancer who had residual 
cancer in the breast or axilla at surgery after neoadjuvant chemotherapy and trastuzumab (14), but it 
was not superior to taxane chemotherapy in a patient population with previously treated HER2-
positive advanced gastric cancer in a randomized trial (15). 
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6XMT-1522 is a novel anti-HER2 ADC containing a human IgG1 anti-HER2 monoclonal antibody 
(HT-19) that binds to domain IV of HER2 to an epitope that is distinct from the trastuzumab 
binding site, and it does not compete with trastuzumab for HER2 binding. In XMT-1522, each 
antibody is armed with an average of 12 auristatin F-hydroxypropylamide (AF-HPA) moieties, 
linked to HT-19 via a cysteine linkage using a biodegradable hydrophilic polymer that enables high 
AF-HPA loading (16) (the structure of XMT-1522 is provided in the Supplement). Both AF-HPA 
and its intracellular catabolite auristatin F (AF) are potent inhibitors of tubulin polymerization (17). 
We compared XMT-1522 to T-DM1 in both T-DM1-sensitive and T-DM1-resistant in vitro and in 
vivo models of breast cancer and gastric cancer, and found XMT-1522 to be in general more 
effective than T-DM1. To our knowledge, this is the first study to demonstrate that XMT-1522 has 
pronounced anti-cancer effect on HER2-positive T-DM1-resistant cancers. 
Materials and methods 
Cell lines 
The cell lines used are summarized in Supplementary table 1. OE-19 was obtained from the 
European Collection of Cell Culture (CAMR Centre for Applied Microbiology and Research, 
Wiltshire, UK), NCI-N87 (N-87) and MCF-7 from the American Type Culture Collection (ATCC, 
Manassas, VA, USA), SNU-216 from the Korean Cell Line Bank (Seoul, Korea), and JIMT-1 from 
the laboratory of Cancer Biology, University of Tampere, Finland (18). The cell lines were cultured 
according to the recommended specifications. 
We generated the T-DM1-resistant HER2-positive gastric cancer cell lines ROE-19 and RN-87 by 
treating OE-19 and N-87 cells, respectively, with increasing concentrations of T-DM1 (Roche Ltd., 
Basel, Switzerland). N-87 and OE-19 cells sensitive to T-DM1 were initially exposed to 0.12 
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7µg/mL or 0.08 µg/mL of T-DM1, respectively, and then to gradually increasing concentrations of 
T-DM1 up to a maximum concentration of 2 µg/mL over 7 months (N-87) or 9 months (OE-19). 
Authentication of cell lines was performed using short tandem repeat analysis. All lines were tested 
for Mycoplasma routinely and only Mycoplasma-free cells were used. 
In vitro assays of cell viability and caspase activation 
The effects of T-DM1 and XMT-1522 (Mersana Therapeutics Inc., Cambridge, MA, USA) on the 
cell growth were studied using the AlamarBlue method (Thermo Fisher Scientific, Waltham, USA). 
The cells were trypsinized and plated in 96-well, flat-bottomed tissue culture plates. The effects of 
T-DM1 and XMT-1522 were tested at concentrations of 0.0001, 0.0006, 0.003, 0.016, 0.08, 0.4, 1, 
2, and 10 µg/mL. The MCF-7 breast cancer cell line with low HER2 expression was used as the 
negative control. The numbers of viable cells were assessed after 5 days of incubation by addition 
of the AlamarBlue reagent (Thermo Fisher Scientific). Fluorescence was measured with excitation 
at 540 nm and emission at 590 nm using a PHERAstar FS plate reader (BMG Labtech, Germany). 
The fluorescence of the samples was normalized to the fluorescence of the cell-free culture media. 
The results are presented as the proportion of viable cells, obtained by dividing the fluorescence of 
the test samples by the fluorescence of the phosphate-buffered saline (PBS)-treated control samples. 
The dose achieving half-maximal (50%) inhibitory concentration (IC50) with the drugs was 
calculated using the Graphpad Prism software (GraphPad Software, San Diego, USA). 
To assess the rate of apoptosis, caspase activation was measured using the Caspase-Glo 3/7 method 
(Promega, Madison, USA) (19). The cells were trypsinised and plated in 96-well flat-bottomed 
tissue culture plates. After overnight culture, the medium was exchanged to a medium containing 
0.0006, 0.003, 0.016, 0.08, 0.4, 1, or 2 µg/mL concentration of either T-DM1 or XMT-1522. After 
48 hours of incubation, 100 µL of the medium was transferred into white-walled 96-well plates, 
mixed with 100 µL Caspase-Glo 3/7 reagent, incubated for 30 min at RT, and the luminescence was 
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8recorded using a PHERAstar FS plate reader (BMG Labtech). The results are presented as 
luminescence units obtained after subtracting the luminescence value from a blank reaction (without 
T-DM1 or XMT-1522 treatment). 
Mouse xenografts 
The National Animal Experiment Board of Finland approved the mouse experiments. Five to 8-
week-old female SCID mice (Envigo RMS B.V., Horst, The Netherlands) were injected 
subcutaneously with 15 × 10
6
 or 18 × 10
6
 of human breast cancer cells (JIMT-1) in 150 μL of the
culture medium (DMEM supplemented with 10% FBS), 14 × 10
6
 of human gastric cancer cells (N-
87), or with 25 × 10
6
 of T-DM1-resistant human gastric cancer cells (RN-87) in 150 μL of the cell
culture medium (RPMI supplemented with 10% FBS) to establish xenograft tumors. Following this, 
T-DM1 (5 mg/kg) or XMT-1522 (1 mg/kg or 3 mg/kg) were administered intravenously (i.v.) at 7-
day intervals. As a control, PBS was administered intraperitoneally (i.p.) at 7-day intervals. Tumor 
size was measured using a caliper, and tumor volume was calculated using the formula Tvol = π/6 × 
larger diameter × (smaller diameter)
2
. Mice with tumor > 20 mm in any one dimension or tumor
ulceration were sacrificed using CO2 inhalations and cervical dislocations. 
Electron microscopy 
Extracellular vesicle (EV) samples were prepared for electron microscopy and imaged as described 
elsewhere (19,20) using an immunostaining procedure. In brief, after paraformaldehyde fixation, 
the samples were blocked with 0.5% bovine serum albumin (BSA) in 0.1 M sodium phosphate 
buffer (pH 7.0) for 10 min at RT, incubated with a 12 nm colloidal gold-conjugated goat-anti-
human-IgG secondary antibody (gold-GAHIG; Jackson ImmunoResearch) in the same sodium 
phosphate buffer for 30 min at RT, washed with the sodium phosphate buffer and deionized water, 
stained with uranyl acetate, and embedded in a methyl cellulose uranyl acetate mixture. The 
samples were viewed using either a Tecnai 12 transmission electron microscope (FEI Company, 
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9Eindhoven, The Netherlands) or a Jeol JEM-1400 transmission electron microscope (Jeol Ltd., 
Tokyo, Japan,), each operating at 80 kV. 
Other methods 
The methods used for RNA isolation, RNA expression analysis, immunohistochemistry, 
fluorescence in situ hybridization, flow cytometry, EV sample preparation and analysis, and the 
nanoparticle tracking analysis are provided in the Supplement. 
Statistical analysis 
Data are expressed as the mean ± SE. Groups were compared using Student’s t test when the data 
passed the normality test. Gene expression data were compared using two-way ANOVA. Unpaired 
groups were compared with the Mann-Whitney test. Survival was analyzed using the Kaplan-Meier 
method, and survival between groups was compared with the log-rank test. Statistical calculations 
were carried out using the IBM SPSS version 24 (IBM, Armonk, USA). All P values are two-sided. 
Results 
XMT-1522 inhibits the growth of T-DM1-resistant cells in vitro 
The growth inhibitory effects of T-DM1 and XMT-1522 were compared in six HER2-positive 
cancer cell lines and in the control cell line (MCF-7) that does not harbor HER2 amplification and 
has a low level of HER2 protein expression (21). XMT-1522 inhibited the growth of all HER2-
positive cell lines in a dose-dependent manner. The proportion of cells surviving the treatments was 
smaller with XMT-1522 than with T-DM1 particularly in the ROE-19, RN-87, and SNU-216 
gastric cancer cell lines that are resistant to T-DM1. The 50% inhibitory concentration (IC50) was 
achieved with XMT-1522 in all six HER2-positive cell lines, but with T-DM1 only in the OE-19, 
N-87, and JIMT-1 cell lines, where XMT-1522 yielded 2.5-fold (OE-19), 3.6-fold (N-87), and 13-
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fold (JIMT-1) greater growth inhibition as compared with T-DM1. The IC50 values of XMT-1522 
on N-87 and RN-87 cell lines (0.010 and 0.011 µg/mL, respectively) and OE-19 and ROE-19 cell 
lines (0.008 and 0.011 µg/mL, respectively) were similar, suggesting similar activity of XMT-1522 
in the parent cell line and the corresponding T-DM1-resistant derivative cell line. As expected, 
neither T-DM1 nor XMT-1522 was effective in the HER2-negative MCF-7 cell line (Fig. 1, A-G). 
To estimate the rate of apoptosis, we studied the influence of T-DM1 and XMT-1522 on caspase-3 
and/or caspase-7 in the HER2-positive cell lines JIMT-1 and RN-87. In both cell lines XMT-1522 
increased caspase-3 and/or caspase-7 activity in a dose-dependent manner more than T-DM1 (Fig. 
1, H & I). 
XMT-1522 eradicates T-DM1-resistant RN-87 xenografts in vivo 
The effects of XMT-1522 and T-DM1 on the growth of RN-87 xenografts was compared in mice. 
The RN-87 gastric cancer xenografts expressed HER2 at the same level as the T-DM1-sensitive 
parental N-87 xenografts (Supplementary Fig. 1, A & B). Tumors formed in all 44 mice inoculated 
with RN-87 cell suspension within 7 days from the date of inoculation reaching a mean tumor 
volume of 39.5 ± 11.4 mm
3 
on day 7. On day 18 since inoculation, the mice were split into four
groups, and were treated weekly with either PBS (n = 12), T-DM1 5 mg/kg (n = 20), XMT-1522 1 
mg/kg (n = 6), or XMT-1522 3 mg/kg (n = 6). T-DM1 did not inhibit tumor growth, whereas both 
doses of XMT-1522 induced rapid and complete tumor shrinkage (Fig. 2, A & B). Six out of the 20 
T-DM1-treated mice were euthanized due to the presence of a large ulcerated tumor by day 35 since 
the inoculation, the T-DM1 treatment of nine mice was discontinued on day 35, and five mice 
continued to receive the T-DM1 treatment. From day 35 onwards four of the nine mice whose T-
DM1 treatment was discontinued were treated with 1 mg/kg of XMT-1522 and five mice with 3 
mg/kg of XMT-1522. All nine mice treated with XMT-1522 following the T-DM1 treatment had 
tumor shrinkage, whereas the five mice that continued on T-DM1 showed persistent tumor growth. 
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Two out of the five mice treated with 3 mg/kg of XMT-1522 were euthanized due to ulceration of 
the tumor on day 43 since the inoculation, and the three remaining mice had unmeasurable tumor by 
day 67. All four tumors treated with 1 mg/kg of XMT-1522 became unmeasurable by day 71. 
XMT-1522 treatment was discontinued for all the remaining animals on day 63 with follow-up until 
day 85. No tumor relapse was observed during the follow-up time. No significant difference in the 
tumor growth rate was observed between the two XMT-1522 dosing groups. 
On day 35 since the date of tumor inoculation three out of the 12 mice allocated to PBS were 
switched to 1 mg/kg of XMT-1522, three to 3 mg/kg of XMT-1522, and three to 5 mg/kg of T-
DM1. The three remaining mice in the PBS group were euthanized due to large ulcerated tumors by 
day 35. The mice treated with T-DM1 had further cancer progression. In contrast, all six mice 
treated with XMT-1522 showed tumor shrinkage. One mouse from the 1 mg/kg XMT-1522 
treatment group and one from the 3 mg/kg group were euthanized due to ulceration of the tumor on 
day 43 and on day 46 since the inoculation, respectively, but the four remaining tumors became 
unmeasurable by day 71 in the 1 mg/kg group and by day 67 in the 3 mg/kg group similar to the 
mice that were switched from T-DM1 to XMT-1522. 
XMT-1522 increased mice survival compared to T-DM1 (P < 0.001; Supplementary Fig. 2A). The 
mice whose T-DM1 treatment was switched to XMT-1522 survived longer than the mice that had 
been treated continuously with T-DM1 (P = 0.010; Supplementary Fig. 2, B). 
XMT-1522 eliminates breast cancer xenografts 
The effects of XMT-1522 and T-DM1 were next compared using a JIMT-1 HER2-positive breast 
cancer xenograft model. Tumors formed in all 32 mice inoculated with the JIMT-1 cell suspension 
by day 7 with a mean tumor volume of 80.6 ± 26.9 mm
3
 on day 7. On day 15 after the inoculation,
the mice were split into four treatment groups, and were treated weekly for 3 weeks with either PBS 
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(n = 10), T-DM1 (5 mg/kg, n = 10), XMT-1522 1 mg/kg (n = 6), or XMT-1522 3 mg/kg (n = 6). 
While the T-DM1-treated tumors grew continuously, tumor shrinkage was rapid in both XMT-1522 
dosing groups. All six mice treated with 3 mg/kg of XMT-1522 and five out of the six mice treated 
with 1 mg/kg of XMT-1522 had no palpable tumor from day 70 onwards. The one remaining tumor 
shrunk from the size of 301.4 mm
3
 on day 15 when XMT-1522 treatment was started to 4.2 mm
3
 on
day 63, and then started to grow reaching 14.1 mm
3
 on day 98. From day 99 onwards this mouse
was treated with XMT-1522 3 mg/kg for three weeks, which resulted in tumor shrinkage to 1.5 mm
3
on day 131. Mice allocated to XMT-1522 survived longer than those allocated to T-DM1 (P < 
0.001; Fig. 3). 
Next, the XMT-1522 and T-DM1 treatments were started at the time of JIMT-1 cell inoculation to 
compare the drug effects on tumor formation. Six mice treated with PBS were used as a control. 
The tumors in the T-DM1-treated mice (n = 18) remained small until day 27, but then started to 
grow. In the two XMT-1522 dosing groups (1 mg/kg and 3 mg/kg, n = 6 each) no tumors were 
detectable from day 20 onwards (Fig. 4, A & B). The mice treated with T-DM1 survived longer 
than the control group mice (P < 0.001) while the mice allocated to XMT-1522 survived longer 
than those treated with T-DM1 (P < 0.001; Fig. 4, C). 
XMT-1522 was also tested in mice that had cancer progression while on T-DM1 5 mg/kg weekly. 
Two of these 18 mice were euthanized due to a large ulcerated tumor by day 43 since the date of 
tumor inoculation. On day 43, ten of the remaining 16 mice had the treatment switched to either 1 
mg/kg of XMT-1522 (n = 5) or 3 mg/kg of XMT-1522 (n = 5), and 6 mice continued with T-DM1 
treatment. The tumors of the 6 mice that continued with T-DM1 treatment progressed, while the 
mice treated with XMT-1522 had rapid tumor shrinkage irrespective of the XMT-1522 dosage (Fig. 
4, A & B). Four out of the 5 mice treated with XMT-1522 3 mg/kg had no palpable tumor from day 
76 onwards, but one tumor became detectable on day 125 and then progressed. Two out of the 5 
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mice treated with XMT-1522 1 mg/kg had no palpable tumor from day 83 onwards, the 3 remaining 
tumors first shrank (to unmeasurable, 14.1 mm
3
, and 6.3 mm
3
), but then started to regrow and
continued to progress despite administration of the 3 mg/kg dose of XMT-1522. The mice that had 
T-DM1 switched to XMT-1522 survived longer than the mice that continued with T-DM1 (P < 
0.001; Fig. 4, D). 
XMT-1522 evokes apoptosis in T-DM1-resistant breast cancer and gastric cancer xenografts 
More apoptotic cells were detected in the RN-87 and JIMT-1 xenografts treated with XMT-1522 
than in tumors treated with T-DM1 (Fig. 5, A-D; Supplementary Fig. 3). A higher number of 
apoptotic cells was present in the JIMT-1 tumor that relapsed after being treated with the 1 mg/kg 
dose of XMT-1522 but was still sensitive to the higher dose (Fig. 5, E), whereas only few apoptotic 
cells were observed in the JIMT-1 tumors that grew during XMT-1522 treatment (Fig 5, F). 
Expression of HER2 and EGFR on T-DM1-treated and XMT-1522-treated JIMT-1 
xenografts 
JIMT-1 tumors treated continuously with T-DM1 retained their HER2 expression, but gained some 
EGFR expression (Supplementary Fig. 4, A-B, F-G). The JIMT-1 tumor that ceased to respond to 1 
mg/kg of XMT-1522 but responded to 3 mg/kg of XMT-1522 remained HER2-positive and EGFR-
negative (Supplementary Fig. 4, D & I). All 4 tumors that progressed on T-DM1 and were 
subsequently treated with XMT-1522 and after an initial response progressed also on XMT-1522 
had lost the HER2 expression, and two of the four progressing tumors expressed slightly also EGFR 
(Supplementary Fig. 4, E & J). Giant multinucleated cells and cells with aberrant mitotic 
morphology, the hallmarks of mitotic catastrophe (22), were observed in both T-DM1-treated and 
XMT-1522-treated xenografts (Supplementary Fig. 4, B-D, G-J). 
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Loss of HER2 amplification in T-DM1-pretreated JIMT-1 xenografts that progressed on 
XMT-1522 treatment 
Interestingly, JIMT-1 tumors that progressed on T-DM1 and were subsequently treated with XMT-
1522 and that after an initial response progressed also on XMT-1522 showed loss of HER2 gene 
amplification unlike JIMT-1 tumors that were continuously treated with T-DM1 (P < 0.0001; 
Supplementary Fig. 5, A-D). 
HER2 and ATP-binding cassette (ABC) transporter mRNA and protein expression in the T-
DM1-resistant cell lines 
To elucidate the mechanisms associated with the T-DM1 resistance, gene expression of the T-DM1-
sensitive parental gastric cancer cell lines (N-87, OE-19) was compared to their resistant 
counterparts (RN-87, ROE-19). Slight down-regulation of HER2 mRNA was detected in the 
resistant cells as compared to the corresponding sensitive cell lines (RN-87 vs. N-87, 1.35-fold 
decrease; ROE-19 vs. OE-19, 1.72-fold decrease). ATP-binding cassette (ABC) transporters may 
cause resistance to anticancer therapy by increasing the efflux of chemotherapy agents from cancer 
cells (23). Substantial upregulation of ABCC2 and ABCG2 mRNA was found in the resistant RN-87 
cells as compared to the sensitive N-87 cells (1385-fold and 116-fold increase, respectively), and 
significant upregulation of ABCC1 and ABCC2 was detected in the resistant ROE-19 cells as 
compared to the sensitive OE-19 cells (98-fold and 37-fold increase, respectively) (Fig. 6, A). 
Flow cytometric analyses of the corresponding protein levels supported these findings. Resistant 
RN-87 and ROE-19 cells had lower cell surface HER2 expression than the sensitive N-87 cells and 
OE-19 cells (P = 0.005 and P = 0.007, respectively; Fig. 6, B). There were no significant 
associations between the drug responses (IC50 values) to either T-DM1 or XMT-1522 and the 
numbers of cell surface HER2 receptors (r = -0.94, P = 0.23; r = -0.49, P = 0.32, respectively) (Fig. 
6, C). The expression of ABCC1, ABCC2, and ABCG2 proteins in the cell lines were in agreement 
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with the corresponding mRNA expression levels. SNU-216 gastric cancer cells had very low levels 
of ABCC1 and ABCG2 (Fig. 6, D-F). 
Inhibition of ABC transporters sensitizes the resistant cells to T-DM1 
To investigate the role of ABC transporters in resistance to T-DM1, three ABC transporter 
inhibitors tetrandrine, MK571, and elacridar were studied either as single agents or in a combination 
with T-DM1 in HER2-positive T-DM1-resistant gastric cancer cell lines RN-87 and ROE-19. 
MK571 (Sigma-Aldrich) is an inhibitor of ABCC1, ABCC2, and ABCG2 (24,25), elacridar 
(Sigma-Aldrich) inhibits ABCB1 and ABCG2 (26), and tetrandrine (Abcam, Cambridge, UK) 
inhibits ABCB1 and ABCC1 (27). Tetrandrine (5 µM), MK571 (50 µM), and elacridar (1 µM) were 
used either alone or combined with T-DM1 at concentrations of 10 µg/mL, 10 µg/mL, and 2 
µg/mL, respectively. In each experiment, the combination of an ABC transporter inhibitor and T-
DM1 resulted in the lowest cell survival (Fig. 6, G-I). These data suggest that overexpression of 
ABCC1, ABCC2, and ABCG2 transporters decreases biological activity of T-DM1 in RN-87 and 
ROE-19 cells. 
T-DM1-resistant cells dispose T-DM1 by extracellular vesicle (EV) secretion 
Cancer cells can dispose T-DM1 by EV secretion (19), and we, therefore, compared this mechanism 
between the T-DM1-sensitive N-87 and T-DM1-resistant RN-87 cells. EVs of 30 to 300 nm in 
diameter were detected by using transmission electron microscopy and no difference in the EV 
particle size distributions were detected between the two cell lines by nanoparticle tracking analysis 
(Supplementary Fig. 6). At immuno-electron microscopy, T-DM1 was present on the surface of 
EVs derived from both N-87 and RN-87 cells treated with T-DM1 (Supplementary Fig. 7, A & B). 
Higher amounts of T-DM1 were found on the EVs prepared from RN-87 cells than on those derived 
from N-87 (P = 0.036) in a flow cytometry analysis suggesting that the resistant cells dispose more 
T-DM1 by secreting EVs than the T-DM1-sensitive cells. The T-DM1 binding capacity (TBC) of 
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the EVs harvested from the RN-87 cells was also higher than that of the EVs harvested from N-87 
cells (P = 0.037; Supplementary Fig. 7, C & D). 
Discussion 
Most cancers treated with T-DM1 eventually progress (12,13), and, therefore, novel agents for 
treating T-DM1-resistant HER2-positive cancers are needed. We report here that both breast and 
gastric cancer cells resistant to T-DM1 are sensitive to XMT-1522, a next generation anti-HER2 
ADC. XMT-1522 had a more pronounced growth inhibitory effect on breast and gastric cancer cells 
sensitive to T-DM1 than T-DM1 in vitro, and XMT-1522 had marked anti-cancer efficacy in vitro 
and in mouse xenograft models of breast cancer and gastric cancer with resistance to T-DM1. 
The biological activity of T-DM1 likely depends on the cytosolic concentration of its cytotoxic 
moiety, DM1. Therefore, the factors that decrease the intracellular DM1 concentration may 
contribute to resistance (11), such as decreased expression of HER2 leading to delivery of less T-
DM1 into the cells (28), and overexpression of drug efflux proteins that can discard DM1 from the 
cells (24,28). In line with these observations, we detected decreased expression of HER2 on the T-
DM1-resistant RN-87 and ROE-19 gastric cancer cells as compared to their sensitive parental cells. 
In addition, the resistant cells expressed higher levels of ABCC1 (multi-drug resistance protein 1), 
ABCC2 (multi-drug resistance protein 2), and ABCG2 (breast cancer resistance protein). Inhibitors 
of these transporters (MK571, elacridar, and tetrandrine) restored the sensitivity of the resistant 
cells to T-DM1, suggesting that these transporters play a role in the T-DM1 resistance in RN-87 and 
ROE-19 cells. We also propose a novel mechanism that can further decrease intracellular DM1 
concentrations. When we compared T-DM1-sensitive and T-DM1-resistant cancer cells (N-87 and 
RN-87, respectively), the secreted extracellular vesicles (EV) derived from the resistant cells 
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contained more HER2 compared to the EVs derived from the sensitive cells (although the resistant 
cells had less cell surface HER2), and more T-DM1 was present on EVs harvested from the T-
DM1-resistant RN-87 cells. Therefore, disposal of T-DM1 on the secreted EVs by the resistant cells 
may contribute to T-DM1 resistance. 
Loss of HER2 expression and increased EGFR expression were linked to the acquired T-DM1 
resistance based on an in vitro JIMT-1 breast cancer cell model (29). We found decreased, but still 
substantial expression of HER2 protein in the T-DM1-resistant JIMT-1 xenografts, and increased 
expression of EGFR. While higher EGFR expression could serve as a growth signal bypassing 
HER2, the mechanisms causing T-DM1 resistance in JIMT-1 cells remain largely unknown. 
We tested three strategies to administer XMT-1522 in mouse xenograft models, and found XMT-
1522 effective in each setting. When XMT-1522 was administered to mice carrying small 
subcutaneous tumors that had not been treated previously, all RN-87 gastric cancer xenografts and 
all but one JIMT-1 breast xenograft shrank rapidly and disappeared. XMT-1522 was also effective 
on larger xenograft tumors that were resistant to T-DM1. In this setting, most RN-87 gastric cancer 
xenografts and most JIMT-1 breast cancer xenografts disappeared during the XMT-1522 treatment. 
Interestingly, several of the few tumors that did not regress completely on XMT-1522 treatment or 
recurred following XMT-1522 treatment were HER2-negative in both immunohistochemistry and 
FISH, suggesting that loss of HER2 expression, which might be caused by loss of HER2 
amplification, is a resistance mechanism to XMT-1522. In the third setting where drug 
administration was started already at the time of tumor cell inoculation mimicking micrometastatic 
disease and the adjuvant setting, XMT-1522 inhibited tumor formation, whereas in the T-DM1-
treated mice the tumors progressed. 
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Retrospective analyses of two phase II trials evaluating T-DM1 showed lower response rates in 
patients with lower HER2 levels (30,31), suggesting that response to T-DM1 depends on the 
amount of tumor HER2 expression even in the subset of cancers that were judged as HER2-
positive. Hypothetically, high response rates may be achieved with ADCs that have a high drug 
antibody ratio (DAR). In XMT-1522 the cytotoxic AF-HPA moieties are conjugated to an anti-
HER2 antibody via a polymer linker that allows high drug loading (16). The higher DAR of XMT-
1522 compared to T-DM1 (12 vs. 3.5, respectively) may in part explain the superior anti-cancer 
efficacy of XMT-1522 in our breast and gastric cancer models as compared to T-DM1. Further 
study is needed to find out whether AF-HPA and its catabolite auristatin F (AF) are less avid 
substrates for the ABCC1, ABCC2, and ABCG2 transporters than lysine-MCC-DM1, the active 
catabolite of DM1.  
The greater anti-cancer effect of XMT-1522 might also be related to the bystander effect. AF-HPA 
is membrane-permeable and can, therefore, enter the neighboring cells where AF-HPA is converted 
to highly cytotoxic but non-cell membrane permeable AF, which is trapped in the cells (17). In 
contrast, lysine-MCC-DM1 that is formed at proteolytic degradation of T-DM1 in the lysosomes 
cannot cross the cell membranes, and, therefore, T-DM1 lacks the bystander effect (9). Both DM1 
and auristatins are highly cytotoxic payloads causing cell death by inhibiting tubulin polymerization 
(31). Antibody-dependent cellular cytotoxicity (ADCC) likely contributes substantially to the 
efficacy of trastuzumab and T-DM1 in vivo (22,32). HT-19, the antibody part of XMT-1522, may 
also evoke ADCC (33). 
In summary, XMT-1522, an anti-HER2 ADC showed a stronger inhibitory effect on breast and 
gastric cancer cells sensitive to T-DM1 than T-DM1. In addition, it was efficacious on gastric 
cancer cells with primary or acquired resistance to T-DM1 in vitro, and XMT-1522 had anti-cancer 
efficacy also in T-DM1-resistant breast cancer and gastric cancer xenografts in vivo. The results 
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support clinical evaluation of XMT-1522 in patients with HER2-posive breast cancer or gastric 
cancer.  
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Figure legends 
Figure 1. 
Effect of T-DM1 and XMT-1522 on the growth (A-G) and caspase activity (H, I) of breast cancer 
and gastric cancer cells lines. Cell growth rate was assessed with the AlamarBlue method and 
apoptosis with the Caspase-Glo 3/7 method. 
Figure 2. 
Effect of T-DM1 and XMT-1522 on the growth of RN-87 xenografts in SCID mice (A). On day 35 
after tumor inoculation the T-DM1 treatment was switched to either XMT-1522 1 mg/kg or XMT-
1522 3 mg/kg in a few mice, and PBS treatment to either XMT-1522 1 mg/kg, XMT-1522 3 mg/kg, 
or T-DM1. (B) The drug administration schedule. 
Figure 3. 
Effect of T-DM1 and XMT-1522 on the growth of JIMT-1 xenografts in SCID mice (A).  The drug 
administration times are indicated with arrows below the X-axis. One tumor treated with XMT-
1522 1 mg/kg started to grow after initial shrinkage and was re-treated with the higher dose of 
XMT-1522 from day 99 onwards (pink arrows). (B) Survival of mice in the four treatment groups 
since the date of tumor inoculation. 
Figure 4 
Effects of T-DM1 and XMT-1522 on the formation of JIMT-1 xenografts (A). On day 43 after 
tumor inoculation a few mice had the treatment switched from T-DM1 to XMT-1522 1 mg/kg or 3 
mg/kg. (B) The drug administration schedule. Survival calculated since the date of tumor 
inoculation (C) or since day 43 (D). 
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Figure 5 
XMT-1522 evokes apoptosis. More apoptotic cancer cells (arrows) were present in RN-87 tumors 
(B) and JIMT-1 tumors (D) treated with XMT-1522 than in those treated with T-DM1 (A, C). Many 
apoptotic cells were present in a JIMT-1 tumor that relapsed after being treated with the 1 mg/kg 
dose of XMT-1522 but was sensitive (s.) to the 3 mg/kg dose of XMT-1522 (E). Few apoptotic 
cells were present in the tumors that progressed first on T-DM1 then on XMT-1522 (r.) (F). The bar 
= 30 µm. 
Figure 6 
Potential resistance mechanisms to T-DM1. (A) Selected differentially expressed mRNAs in T-
DM1 sensitive (N-87 and OE-19) and resistant (RN-87 and ROE-19) HER2-positive gastric cancer 
cell lines in a gene expression microarray. (B) Flow cytometric quantification of HER2 in seven cell 
lines. T-DM1-resistant RN-87 and ROE-19 cells had lower levels of HER2 compared to the T-
DM1-sensitive N-87 and OE-19 cells (P = 0.005 and P = 0.007, respectively). (C) Associations 
between the drug responses (IC50 values) and the numbers of cell surface HER2 receptors. (D-F) 
Flow cytometric quantification of ABCC1, ABCC2, and ABCG2 expression in T-DM1-sensitive 
and T-DM1-resistant gastric cancer cell lines. ABCC1: N-87 vs. RN-87, P = 0.0030; OE-19 vs. 
ROE-19, P = 0.0059. ABCC2: N-87 vs. RN-87, P = 0.1872; OE-19 vs. ROE-19, P = 0.0038. 
ABCG2: N-87 vs. RN-87, P = 0.0013; OE-19 vs. ROE-19, P = 0.0184. (G-I) The effect of ABC 
transporter-inhibitors tetrandrine, MK571, and elacridar as single agents or in combination with T-
DM1 in RN-87 (G, H) and ROE-19 (I) cells. The combination resulted in the lowest cell survival. 
T-DM1 vs. tetrandrine + T-DM1, P = 0.0017; T-DM1 vs. MK571 + T-DM1, P = 0.0023; T-DM1 
vs. elacridar + T-DM1, P = 0.0001. 
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